PDC*line Pharma

PDC*line Pharma is a French-Belgium clinical-stage biotech company that develops a new class of active immunotherapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC*line) loaded with cancer antigens. PDC*mel, our first drug candidate is currently in phase 1 clinical trials for melanoma. PDC*lung is in preclinical development for lung cancer. Our approach can be applied to virtually any type of cancer and any patient population, and combined with differents cancer treatments.
Company Growth (employees)
Grenoble, FR
Size (employees)
12 (est)+34%
PDC*line Pharma was founded in 2014 and is headquartered in Grenoble, FR

PDC*line Pharma Office Locations

PDC*line Pharma has offices in Grenoble and Liège

PDC*line Pharma Data and Metrics

Summary Metrics

Founding Date


Total Funding

$4.3 m

Latest funding size

$4.3 m

Time since last funding

9 months
PDC*line Pharma's latest funding round in December 2016 was reported to be $4.3 m. In total, PDC*line Pharma has raised $4.3 m

Traffic Overview of PDC*line Pharma

PDC*line Pharma News and Updates

Term Sheet — Wednesday, December 7

On deals and dealmakers.

PDC*line Pharma Company Life and Culture

You may also be interested in